These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

308 related items for PubMed ID: 7706943

  • 1. Physiologic mechanisms of action of lovastatin in nephrotic syndrome.
    Aguilar-Salinas CA, Barrett PH, Kelber J, Delmez J, Schonfeld G.
    J Lipid Res; 1995 Jan; 36(1):188-99. PubMed ID: 7706943
    [Abstract] [Full Text] [Related]

  • 2. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB-containing lipoproteins: implications for the pathophysiology of apoB production.
    Arad Y, Ramakrishnan R, Ginsberg HN.
    J Lipid Res; 1990 Apr; 31(4):567-82. PubMed ID: 2351867
    [Abstract] [Full Text] [Related]

  • 3. Lovastatin decreases de novo cholesterol synthesis and LDL Apo B-100 production rates in combined-hyperlipidemic males.
    Cuchel M, Schaefer EJ, Millar JS, Jones PJ, Dolnikowski GG, Vergani C, Lichtenstein AH.
    Arterioscler Thromb Vasc Biol; 1997 Oct; 17(10):1910-7. PubMed ID: 9351353
    [Abstract] [Full Text] [Related]

  • 4. The magnitude of decrease in hepatic very low density lipoprotein apolipoprotein B secretion is determined by the extent of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibition in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Endocrinology; 1999 Nov; 140(11):5293-302. PubMed ID: 10537160
    [Abstract] [Full Text] [Related]

  • 5. Influence of atorvastatin and simvastatin on apolipoprotein B metabolism in moderate combined hyperlipidemic subjects with low VLDL and LDL fractional clearance rates.
    Forster LF, Stewart G, Bedford D, Stewart JP, Rogers E, Shepherd J, Packard CJ, Caslake MJ.
    Atherosclerosis; 2002 Sep; 164(1):129-45. PubMed ID: 12119202
    [Abstract] [Full Text] [Related]

  • 6. Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
    Watts GF, Barrett PH, Ji J, Serone AP, Chan DC, Croft KD, Loehrer F, Johnson AG.
    Diabetes; 2003 Mar; 52(3):803-11. PubMed ID: 12606523
    [Abstract] [Full Text] [Related]

  • 7. Inhibition of HMG-CoA reductase by atorvastatin decreases both VLDL and LDL apolipoprotein B production in miniature pigs.
    Burnett JR, Wilcox LJ, Telford DE, Kleinstiver SJ, Barrett PH, Newton RS, Huff MW.
    Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):2589-600. PubMed ID: 9409231
    [Abstract] [Full Text] [Related]

  • 8. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100.
    Zulewski H, Ninnis R, Miserez AR, Baumstark MW, Keller U.
    J Lipid Res; 1998 Feb; 39(2):380-7. PubMed ID: 9507998
    [Abstract] [Full Text] [Related]

  • 9. Lovastatin therapy in nephrotic hyperlipidemia: effects on lipoprotein metabolism.
    Vega GL, Grundy SM.
    Kidney Int; 1988 Jun; 33(6):1160-8. PubMed ID: 3165483
    [Abstract] [Full Text] [Related]

  • 10. Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
    Chan DC, Watts GF, Barrett PH, Mori TA, Beilin LJ, Redgrave TG.
    J Clin Endocrinol Metab; 2002 May; 87(5):2283-9. PubMed ID: 11994377
    [Abstract] [Full Text] [Related]

  • 11. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men.
    Millar JS, Lichtenstein AH, Cuchel M, Dolnikowski GG, Hachey DL, Cohn JS, Schaefer EJ.
    J Lipid Res; 1995 Jun; 36(6):1155-67. PubMed ID: 7665994
    [Abstract] [Full Text] [Related]

  • 12. A familial combined hyperlipidemic kindred with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy.
    Aguilar-Salinas CA, Hugh P, Barrett R, Pulai J, Zhu XL, Schonfeld G.
    Arterioscler Thromb Vasc Biol; 1997 Jan; 17(1):72-82. PubMed ID: 9012640
    [Abstract] [Full Text] [Related]

  • 13. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes.
    Vergès B, Florentin E, Baillot-Rudoni S, Monier S, Petit JM, Rageot D, Gambert P, Duvillard L.
    Diabetologia; 2008 Aug; 51(8):1382-90. PubMed ID: 18535816
    [Abstract] [Full Text] [Related]

  • 14. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia.
    Broyles FE, Walden CE, Hunninghake DB, Hill-Williams D, Knopp RH.
    Am J Cardiol; 1995 Jul 13; 76(2):129A-135A. PubMed ID: 7604788
    [Abstract] [Full Text] [Related]

  • 15. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins.
    Arad Y, Ramakrishnan R, Ginsberg HN.
    Metabolism; 1992 May 13; 41(5):487-93. PubMed ID: 1588827
    [Abstract] [Full Text] [Related]

  • 16. Overproduction of small very low density lipoproteins (Sf 20-60) in moderate hypercholesterolemia: relationships between apolipoprotein B kinetics and plasma lipoproteins.
    Gaw A, Packard CJ, Lindsay GM, Griffin BA, Caslake MJ, Lorimer AR, Shepherd J.
    J Lipid Res; 1995 Jan 13; 36(1):158-71. PubMed ID: 7706941
    [Abstract] [Full Text] [Related]

  • 17. Apolipoprotein B metabolism and the distribution of VLDL and LDL subfractions.
    Packard CJ, Demant T, Stewart JP, Bedford D, Caslake MJ, Schwertfeger G, Bedynek A, Shepherd J, Seidel D.
    J Lipid Res; 2000 Feb 13; 41(2):305-18. PubMed ID: 10681415
    [Abstract] [Full Text] [Related]

  • 18. Mechanism of action of a peroxisome proliferator-activated receptor (PPAR)-delta agonist on lipoprotein metabolism in dyslipidemic subjects with central obesity.
    Ooi EM, Watts GF, Sprecher DL, Chan DC, Barrett PH.
    J Clin Endocrinol Metab; 2011 Oct 13; 96(10):E1568-76. PubMed ID: 21816786
    [Abstract] [Full Text] [Related]

  • 19. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B.
    Vega GL, East C, Grundy SM.
    Atherosclerosis; 1988 Mar 13; 70(1-2):131-43. PubMed ID: 3162680
    [Abstract] [Full Text] [Related]

  • 20. Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.
    Milosavljevic D, Griglio S, Le Naour G, Chapman MJ.
    Atherosclerosis; 2001 Mar 13; 155(1):251-60. PubMed ID: 11223449
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.